Introduction: [ 18 F]FMISO, the widely used positron emission tomography (PET) hypoxia tracer, is a chiral compound clinically used as a racemic mixture. The purpose of this study was to synthesize the individual (R)-and the (S)-enantiomers of [ 18 F]FMISO and compare their PET imaging characteristics.
Introduction
Inefficient angiogenesis during growth of solid tumors often leads to spatial and temporal deficiency in their oxygen supply. When the partial pressure of oxygen decreases significantly a condition of oxygen starvation, or hypoxia, occurs. Tumor cells respond to hypoxia by activating several isoforms of hypoxia inducible factor HIF [1] , which, together with various microRNAs [2] regulate gene expression responsible for glycolysis, apoptosis, DNA repair, and angiogenesis in tumor cells. As a consequence, hypoxia increases tumor cell invasion [3] , activates autophagy [4] and promotes tumor motility [5] and cell pluripotency [6] . Importantly, hypoxia often increases resistance of cancer cells to chemotherapy and radiotherapy [7] . In clinical settings, the determination of hypoxia status could provide important information to stratify patients to optimize treatment, including hypoxic radiosensitizers and hypoxia guided radiation therapy. Presently, a number of methods for detection and measuring tumor hypoxia are available, such as the Eppendorf needle electrode, immunostaining, fluorescence and diffuse reflectance spectroscopy [8] . In the 1980s, positron emission tomography (PET) emerged as a noninvasive, viable-cell specific, highly sensitive quantitative hypoxia accessing modality. Subsequently, a A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT series of 2-nitro-imidazoles labeled with fluorine-18 in a position peripheral to the imidazole ring was developed and successfully used to measure hypoxia [9] . Among these, (
is currently the most used hypoxia PET tracer ( Fig. 1 ).
Central to the structure-activity relationship of [ 18 F]FMISO is a redox-active 2-nitroimidazole ring, which allows the molecule to accept terminal electrons from the respiratory cycle. In hypoxic regions, where the concentration of dioxygen is too low to re-oxidize the initially formed -NO2·-, the anion radical undergoes further reduction to -NH2, and the resulting species binds covalently to the macromolecules.
[ 18 F]FMISO is a chiral compound, which is currently used as a racemic mixture in PET. It is well known that chirality may affect the affinity and/or efficacy of drugs [10] , and different enantiomers may display different pharmacokinetic profiles [11] . Several factors may cause such differences. In particular, binding to tissue and plasma proteins, primarily to albumin, as well as to lipoproteins and red blood cells can be stereoselective [11, 12] . As this binding affects the plasma concentration of free drug, this could in turn affect the rates of excretion and degradation and ultimately plasma half-life and biodistribution. In addition, active renal excretion and reabsorption, as well as enzymatic drug metabolism [11] have been shown to be stereoselective in certain cases [11, 13] . Therefore, it is generally important to determine if different enantiomers of a drug have different in vivo efficacy based on stereoselective pharmacokinetics. Further, in the special case of [ 18 F]FMISO, the electron transport to the 2nitroimidazole ring can be mediated by a variety of chiral macromolecules, including nitroreductase enzymes [14] . For these reasons, the question arises as to what degree the imaging characteristics of the two enantiomers of [ 18 F]FMISO differ. In the field of nuclear medicine, this is particularly important, as the use of the more active enantiomer could potentially decrease the amount of administered radioactivity, and thus the dose to the patient. In addition, if one enantiomer is more specific, the use of this enantiomer could enhance image quality. Herein, we report an enantiospecific, single-step radiosynthesis of both enantiomers of [ 18 F]FMISO. The biodistribution and imaging abilities of (S)-and (R)-[ 18 F]FMISO were evaluated by PET in FaDu tumor xenograft bearing mice.
Materials and methods

General
Chemicals were purchased from Sigma-Aldrich and ABX GmbH and used without further purification unless stated otherwise. 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was purified by sequential passing through silica, and activated alumina followed by vacuum distillation. Acetonitrile (ACN), ethyl acetate (EtOAc), and dichloromethane (DCM) were dried over 3 Å molecular sieves. All reactions were performed without exclusion of moisture and air. The silica cartridges (Supelco, 4 g) were preconditioned with hexane. The HPLC and radio-HPLC measurements were performed on a Hitachi EliteChrom equipped with Carrol & Ramsey 105-S radiodetector. The normal phase chiral HPLC/radio-HPLC was done with a Chiralpak AD-3, 150 × 2.1 mm column using hexane/i-PrOH (10:1) isocratic 
Starting materials and references
The reference racemic FMISO was purchased from ABX GmbH. The reference enantiopure FMISO (both enantiomers) were prepared according to the reported procedure [15] . (R)-and (S)-2-nitro-1-(oxiran-2ylmethyl)-1H-imidazoles, the ((R) and (S)-MISO-epoxides) were synthesized similarly to the previously described protocol [16] : a stirred suspension of 2-nitroimidazole (1.00 g, 8.84 mmol, 1.0 eq) and cesium carbonate (145 mg, 0.44 mmol, 0.05 eq.) in dry ethanol (20 mL) was treated with the (R)-or the (S)epichlorohydrin (760 μL, 9.60 mmol, 1.1 eq.), and the resulting mixture was refluxed for 1 h under argon. The hot solution was filtered through glass wool; solids were washed with hot ethanol (10 mL). The reaction mixture was concentrated in vacuo and cooled to -20°C. The resulting off-white precipitate of 1-(2-hydroxy-3-chloropropyl)-2-nitroimidazole was dissolved in 20 mL of EtOAc and treated with aqueous NaOH (10% (w/v), 20 mL). After stirring for 1 h the organic layer was separated, dried over Na 2 SO 4 giving after solvent removal 1.31g (88%) of (S)-MISO-epoxide or 1.26 g (85%) of (R)-MISOepoxide.
2.2.2. Automated radiosynthesis, purification of (R)-and (S)-MISO, and quality control. 
ACCEPTED MANUSCRIPT
pH was measured using pH paper and the residual organic solvent test was performed using GC. The specific activity was estimated from a 5-point calibration curve using UV-VIS spectroscopy and found to exceed 100 GBq/μmol.
Animals and cell lines
All included animal experiments were approved by the Danish Animal Welfare Council, Ministry of Justice. Five week old female NMRI nude mice were purchased from Taconic Europe. Throughout the experiments the animals had ad libitum access to chow and water. After the mice arrived at the animal facility they were allowed to acclimatize for one week. Human pharyngeal squamous cell carcinoma (FaDu) cells, purchased from American Type Culture Collection (ATCC), were cultured in Minimum Essential Medium (MEM) with Earle's salts and sodium bicarbonate supplemented with 2 mM Lglutamine (both from Sigma-Aldrich), 1 mM sodium pyruvate, 1% MEM non-essential amino acids solution (100x), 10% fetal calf serum, 100 units/mL penicillin and 100 μg/mL streptomycin (all from Invitrogen) at 37 °C in 5% CO 2 . Tumors were established by subcutaneous injections of 10 6 cancer cells, dissolved in 100 μL of a (1:1) mixture of cell culture medium and Matrixgel™ (BD-Biosciences), into each flank. Tumors were allowed to grow for two weeks reaching a size of 100-280 mm 3 .
PET imaging
Animals were anesthetized by breathing 3% sevoflurane (Abbot Scandinavia) dissolved in a medical grade 35% oxygen/nitrogen gas mixture and the body temperature was kept stable by a heating pad. Mice with similar tumor sizes were evenly distributed between the two groups and had either (S)- . PET and CT images were coregistered and visually inspected. Regions of interest (ROIs) were manually created on tumors and sections of liver, heart, bladder, kidney and hind limb muscle tissue and the uptake quantified as percent of injected dose per gram (%ID/g). An average value from ROIs created on both left and right side on the animal was calculated for kidney and muscle uptake. Using the same setup time activity curves were generated from the dynamic datasets and the average uptake in the quantified tissue determined. Additionally, the tumor-to-muscle (T/M) and tumor-to-liver (T/L) ratios were calculated for all animals. .
Statistical analysis
All statistical analyses were performed in GraphPad Prism 6 (GraphPad Software). The uptake of (S)-[ 18 F]FMISO and (R)-[ 18 F]FMISO was compared in different tissue using unpaired t-test with correction for multiple comparison using the Holm-Sidak method. Differences were considered significant at the 95% confidence level (p < 0.05).
Results and discussion
3.1. Automated radiosynthesis of (R)-and (S)-[ 18 F]FMISO and quality control.
To the best of our knowledge the only synthesis of both enantiopure FMISO antipodes was performed with fluorine-19 at natural abundance level [17] . Our approach to radiosynthesis of enantiopure (R)-and (S)-[ 18 F]FMISO was based on a recently disclosed transition metal mediated enantioselective epoxide opening which utilized [ 18 F]HF in a combination with (-)tetramisole and (R,R)-Co(salen) [18] . To maximize the enantiomeric purity of the desired (R)-and (S)-[ 18 F]FMISO the radiosynthesis was performed on enantiopure substrates. Due to a notable cooperative effect [15] the stereochemically matched enantiomers of Co(salen) were used (Scheme 1):
The radiosynthesis was automated using a custom-made automatic synthesizer controlled by LabView software (Fig. 2) .
The [ 18 F]HF generator described by us earlier [19, 20] was integrated within the automatic radiosynthesis platform (Fig.2 , top) . After [ 18 F]HF transfer the [ 18 F]HF/(-)tetramisol mixture was transferred into the reaction vial containing a solution of (R)-or (S)-MISO-epoxides and (R,R)-or (S,S)-Co(salen) (Fig.2, bottom) . After reaction, the reaction mixture was transferred onto a silica cartridge and the product was purified by gradient elution. The organic solvent was removed and the dry product collected in the product vial was dissolved in PBS and filtered through a sterile filter.
The final formulation of (R)-and (S)-[ 18 F]FMISO passed the pH test (pH=7.0-7.5). The residual organic solvents (ACN and DCM) were below the limit of detection. The identity of the synthesized [ 18 F]FMISO was confirmed by radio-HPLC and HPLC against the reference sample purchased from ABX GmbH. The HPLC analysis revealed no significant absorption at 254 nm, and radio-HPLC showed that the radiochemical and enantiomeric purities of the (R)-and the (S)-enantiomers of [ 18 F]FMISO were higher than 99% (Fig. 3 ). Table 1 shows the PET-derived tissue uptake in different organs. Both enantiomers showed pronounced abdominal distribution dominated by renal and, to a lesser degree, hepatobiliary clearance. There was no visual variation in the contrast between the PET images acquired within the two groups. The uptake of (R)-and (S)-[ 18 F]FMISO in the liver, heart, kidney, bladder and muscle tissue were the same, within the error of experiment, both 1 and 3 hours p.i. Importantly, there was no significant difference in the tumor accumulation between the two groups. Generally, the tumor uptake was between 2.0-2.5 %ID/g 1 hour p.i. decreasing to 1.0-1.5 %ID/g 3 hours p.i. This also resulted in compatible T/M-ratio with (R)and (S)-[ 18 F]FMISO increasing from 1.6 ± 0.2 and 1.4 ± 0.3 1 hour p.i. to 3.7 ± 0.7 and 3.6 ± 1.3 3 hours p.i., respectively. In addition, no significant difference was seen in the T/L-ratio both 1 and 3 hours p.i. ( Figure 5 ).
PET evaluation of (R)-and (S)-[ 18 F]FMISO
A somewhat different picture emerged from the 2 hours dynamic PET imaging (Fig. 6) . When the mean time activity curves from the two enantiomers were compared, a faster uptake of the (R)-form was observed in tumor tissue. The difference got progressively smaller with time. However, a similar trend was seen in muscle and liver tissue and no difference was observed between the mean T/M-and T/Lratios of (S)-[ 18 F]FMISO and (R)-[ 18 F]FMISO during the 2 hours dynamic scan. The nature of the higher initial affinity of the (R)-isomer is unclear at the moment.
Conclusion
In conclusion, the individual enantiopure (R)-and (S)-enantiomers of [ 18 F]FMISO were synthesized using a novel approach based on Co(salen) mediated epoxide opening with [ 18 F]HF. The PET imaging characteristics of the (R)-and (S)-forms were compared in mice bearing subcutaneous FaDu tumor xenografts. Although the (R)-enantiomer of [ 18 F]FMISO demonstrated a somewhat faster initial tumor, liver and muscle uptake the T/M-and T/L ratios for the (R)-and (S)-forms were the same at all times. Image-derived biodistribution showed no significant differences in tissue uptake for the (R)-and (S)forms 1 and 3 hours after administration. On the basis of these studies we can conclude that the use of enantiopure [ 18 F]FMISO presents no practical clinical benefits for PET imaging.
